lercanidipine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lercanidipine is an antihypertensive drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.   Wikipedia

Chemistry

  • SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1
  • InChIKey: ZDXUKAKRHYTAKV-UHFFFAOYSA-N
  • Mol. Mass: 611.74
  • ALogP: 6.48
  • ChEMBL Molecules:
    lercanidipine  
    lercanidipine hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0653 - $0.1935
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

biohorm brand of lercanidipine hydrochloride | cardiovasc | carmen | corifeo | lercadip | lercan | lercanidipine | lercanidipine hcl | lercanidipine hydrochloride | lercanil | lercapin | lercaton | lerdip | lerkamen | lerzam | masnidipine | methyl-1,1-dimethyl-2-(n-(3,3-diphenylpropyl)-n-methylamino)ethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | rec 15-2375 | rec-15-2375 | rec-15/2375 | renovia | vasodip | zandip | zanicor | zanidip

Organizations (13)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Cardiovascular Diseases (Phase 4)

Essential Hypertension (Phase 4)

HIV Infections (Phase 4)

Hypertension (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue